As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: June 21, 2012
by Medical XPress:
Australian researchers have found biomarkers in the blood that could help develop a test to identify people in the early stages of Alzheimer’s disease.
University of New South Wales School of Psychiatry Professor Perminder Sachdev and his team looked at apolipoproteins, which transport cholesterol in the blood, and found they were dysregulated – or abnormal – in patients with mild cognitive impairment. The research findings are published in the journal PLOS ONE.
“Essentially, this is one step towards developing a suite of biomarkers to include a number of different proteins that will identify individuals with mild cognitive impairment who will probably go on to develop Alzheimer’s disease or dementia in the future,” Professor Sachdev says.
Evidence suggests these proteins are involved in Alzheimer’s disease and some other brain diseases, Professor Sachdev says.
The researchers examined the group of apolipoproteins in the blood of more than 1,000 study participants over a two-year period. About half of the group also had Magnetic Resonance Imaging brain scans and were rated according to their cognitive impairment.
“Apolipoproteins have been of interest in Alzheimer’s disease for a number of reasons,” Professor Sachdev says.
“It is know that one variant of the gene for one type of apolipoprotein, Apo E, increases the risk of Alzheimer’s. Another of these proteins, Apo J or clusterin, has been found in the brain lesions of people with Alzheimer’s.
“We found abnormal levels of clusterin but also some other apolipoproteins in the blood of older individuals with memory problems, and these levels tended to predict who showed worsening of their mental functions over two years.”
As early indicators of cognitive decline, these apolipoproteins may also become targets of treatment or preventative healthcare measures, the authors say.
A new comprehensive study from Florida State University (FSU) finds no evidence to support the idea that personality changes begin before the clinical onset of mild cognitive impairment (MCI) or dementia. MCI is an intermediate...
On the evening of Monday November 27th, join us for conversation and cocktails with award-winning journalist, editor and author Tina Brown, and Indigo’s CEO Heather Reisman. Hear from Tina Brown about her eight-year tenure at Vanity...
The presence of TAR DNA-binding protein 43 (TDP-43) in the hippocampus on postmortem examination is associated with increased rates of hippocampal atrophy in patients with Alzheimer’s disease (AD), new research suggests. This association was greatest...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.